Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer

References

• QuoixERamlauRWesteelVTherapeutic vaccination with tg4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialLancet Oncol2011121125113322019520
   PubMed Web of Science ®Google Scholar
• Le PéchouxCRole of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new dataOncologist20111667268121378080
   PubMed Web of Science ®Google Scholar
• IhdeDCChemotherapy of lung cancerN Engl J Med1992327143414411328881
   PubMed Web of Science ®Google Scholar
• FruschNBosqueeLLouisRlung cancer epidemiology and etiologic factorsRev Med Liege200762954855317966790
   PubMedGoogle Scholar
• WeissJStinchcombeTETreatment of elderly patients with stage IV non-small-cell lung cancerExpert Rev Anticancer Ther20121211112022149437
   PubMed Web of Science ®Google Scholar
• GridelliCAaproMArdizzoniATreatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panelJ Clin Oncol2005233125313715860872
   PubMed Web of Science ®Google Scholar
• GridelliCMaionePRossiAPalazzoloGColantuoniGRossiEManagement of unfit older patients with advanced NSCLCCancer Treat Rev20093551752119457617
   PubMed Web of Science ®Google Scholar
• MaemondoMMinegishiYInoueAFirst-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 studyJ Thorac Oncol201271417142222895139
   PubMed Web of Science ®Google Scholar
• AltundagOStewartDJFossellaFVMany patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyJ Thorac Oncol2007214114617410030
   PubMed Web of Science ®Google Scholar
• MillerABHoogstratenBStaquetMWinklerAReporting results of cancer treatmentCancer1981472072147459811
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst20009220521610655437
   PubMed Web of Science ®Google Scholar
• HaberDABellDWSordellaRMolecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitorsCold Spring Harb Symp Quant Biol20057041942616869779
   PubMedGoogle Scholar
• WangSWongMLHamiltonNDavorenJBJahanTMWalterLCImpact of age and comorbidity on non-small-cell lung cancer treatment in older veteransJ Clin Oncol2012301447145522454424
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGUpdated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl 157520
   Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• SocinskiMACrowellRHensingTETreatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)Chest2007132277S289S17873174
   PubMed Web of Science ®Google Scholar
• HeskethPJLilenbaumRCChanskyKChemotherapy in patients ≥80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6J Thorac Oncol2007249449817545843
   PubMed Web of Science ®Google Scholar
• SemrauSZettlHHildebrandtGKlautkeGFietkauROlder patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapyStrahlenther Onkol20141901125113225098688
   PubMed Web of Science ®Google Scholar
• QiWXTangLNHeANShenZLinFYaoYDoublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysisLung201219047748522711060
   PubMed Web of Science ®Google Scholar
• GotoYSekineIYamadaKInfluence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small-cell lung cancer patientsJ Thorac Oncol2008341241618379361
   PubMed Web of Science ®Google Scholar
• GuckenbergerMKavanaghAPartridgeMCombining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancerStrahlenther Onkol201218889490022933031
   PubMed Web of Science ®Google Scholar
• BreenDBarlesiFZemerliMResults and impact of routine assessment of comorbidity in elderly patients with non-small-cell lung cancer aged >80 yearsClin Lung Cancer2007833133417562233
   PubMed Web of Science ®Google Scholar